In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Edelmira Sánchez-RecillasCenter for Advanced Biomedical Research, School of Medicine, Autonomous University of Queretaro, Campus Aeropuerto Carretera a Chichimequillas S/N, Ejido Bolaños, Querétaro 76140, Mexico.ORCID 0009-0006-4033-594X Enrique Almanza-AguileraUnit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), 08908 Barcelona, Spain.ORCID 0000-0002-4805-0774 David Bars-CortinaUnit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), 08908 Barcelona, Spain.ORCID 0000-0002-8808-7803 Raúl Zamora-RosUnit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), 08908 Barcelona, Spain.ORCID 0000-0002-6236-6804 Rosa Iris Godínez-SantillánCenter for Advanced Biomedical Research, School of Medicine, Autonomous University of Queretaro, Campus Aeropuerto Carretera a Chichimequillas S/N, Ejido Bolaños, Querétaro 76140, Mexico.ORCID 0000-0002-4240-9379 Ana Alicia Sánchez-TusiéCenter for Advanced Biomedical Research, School of Medicine, Autonomous University of Queretaro, Campus Aeropuerto Carretera a Chichimequillas S/N, Ejido Bolaños, Querétaro 76140, Mexico.
Haydé Azeneth Vergara-CastañedaCenter for Advanced Biomedical Research, School of Medicine, Autonomous University of Queretaro, Campus Aeropuerto Carretera a Chichimequillas S/N, Ejido Bolaños, Querétaro 76140, Mexico.ORCID 0000-0001-8926-2223 Funding
Autonomous University of Queretaro - FONFIVE FME202404Secretaría de Ciencia, Humanidades, Tecnología e Innovación 1560335
6 · The paper itselfAbstract
Bioactive compounds in food contribute to reducing the risk of developing colon cancer by modulating the gut microbiota. We have recently demonstrated that garambullo (
Indexed as
Colonic NeoplasmsGastrointestinal MicrobiomePlant ExtractsAnimalsAzoxymethaneBacteriaDextran SulfateDisease Models, AnimalFecesMaleRatsRats, Sprague-DawleyRNA, Ribosomal, 16SAzoxymethaneDextran SulfatePlant ExtractsRNA, Ribosomal, 16Sbioactive compoundschemopreventioncolon cancergarambullogut microbiota
Identifiers
PMID41596659
PMCPMC12842398
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390